INMB INmune Bio Inc

$INMB This will be the 1st year INMB will not be a tax loss candidate!! I believe gap fill at $3.....I think we see $5 in the next 3 months.

$INMB Upcoming Catalyst Sept/Early October In August, INMB said it was targeting the UK Marketing Authorization Application for Ebstrocel in Q4 2026. Earlier guidance had been even more specific: by the end of Q3 or early Q4. That makes late September through October a very realistic window. The upcoming regulatory milestones for Ebstrocel™ represent critical value drivers for INmune Bio Inc., with upcoming UK and EU filings validating manufacturing standards and accelerating the transition to a commercial-stage company. Additionally, a potential U.S. FDA rare pediatric disease approval could yield a Priority Review Voucher worth approximately $100 million, providing substantial non-dilutive capital and driving significant stock volatility.

$INMB looking forward to the upcoming major catalyst. That’s why I have my position here. However, there is also a significant short position in this stock. Can be quite interesting to see what happens when the news breaks. Total Shares Short: ~2.18M – 2.38M shares Short % of Float: ~10.84% Short % of Shares Outstanding: ~7.87% – 8.97% 

$INMB David Moss, Founder and Chief Executive Officer, will be hosting one-on-one meetings with institutional investors on September 14 - 16 and will be presenting on Monday, September 14 at 10:30am

$INMB where's that Priority Review Voucher ? Now would be a good time to drop that little dumpling.

$INMB I use GoNoGo to help time Buys and Sells. It just signaled a Go signal . Last time we had a Go signal was late June 30th at $1.50 and stock ran to $2.15 on July 15th. We had some selling pressure yesterday, which has abated. Major upcoming catalysts that can easily move the stock, especially with 2M shares short. Expecting highe rprices ahead. GoNoGo Charts combines trend, momentum, volume, and volatility into one simplified technical system. It’s useful because it helps quickly identify whether a stock is in a healthy trend, weakening, or potentially reversing without relying on a single indicator. Its strength is that it combines several trend and momentum measures into a weight-of-the-evidence signal, which can reduce false conclusions from relying on one indicator alone.